resistant (9, 10) , a condition usually defined by at least 1 attack per month (8) (9) (10) ; ;10-20% of patients are either resistant to, partially responsive, or intolerant to treatment with colchicine (9, 10) .
The reasons for colchicine failure in patients with colchicine-resistant FMF are unknown. Because the exact molecular bases of FMF flares and the prophylactic effects of colchicine are still obscure, targeted treatments aimed at the pathogenic mechanisms of colchicine nonresponsiveness are not available. Suggested therapeutic alternatives for patients in whom oral colchicine treatment has been ineffective include thalidomide, interferon alpha, intravenous colchicine, and tumor necrosis factor blockers (11) (12) (13) . All of these treatments are limited by insufficient effect, safety concerns, unavailability, and high price, and none has been approved by a regulatory body. Thus, patients with colchicine-resistant FMF continue to have serositis attacks, and are at increased risk of dying from amyloidosis or developing other conditions related to chronic inflammation (14) .
Anakinra is a recombinant human IL-1 receptor antagonist, and is used for the treatment of rheumatoid arthritis (RA), cryopyrin-associated periodic syndrome (CAPS), and adult and juvenile forms of Still's disease. Various studies have demonstrated that anakinra has an acceptable safety profile (see refs. 15-19; further information is available at http://www.fda.gov). Over the last several years, evidence of an important role for anakinra in the prevention of serositis attacks in patients with colchicine-resistant FMF has emerged. To date, more than 20 published studies, comprising ;60 patients, have shown a beneficial effect of anakinra in the treatment of colchicine-resistant FMF, with evidence of clinical and laboratory improvements, including reductions in the attack rate and in serum levels of inflammatory proteins (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) . However, no randomized controlled trial has been conducted. The aim of the present study was to assess the efficacy and safety of anakinra for the treatment of colchicine-resistant FMF by means of a randomized controlled trial.
PATIENTS AND METHODS
Study design. This was a single-center, investigatorinitiated study. It was conducted as a double-blind, randomized, placebo-controlled trial to examine the ameliorating effect of anakinra treatment in patients with colchicine-resistant FMF over a period of 4 months. The Institutional Review Board (IRB) of Sheba Medical Center approved the study. Until anakinra is approved for the treatment of colchicine-resistant FMF, open-label anakinra was not requested by the IRB, since the study was categorized as an investigator-initiated trial.
Patients. Inclusion criteria. Patients enrolled in the study were adults with FMF (age range $18 years to #65 years) who were diagnosed according to the Tel Hashomer criteria (32) , who were carriers of at least 2 MEFV mutations, who had experienced at least 1 attack per month in any of the 4 FMF sites (abdomen, chest, joints, skin) despite having received a maximal tolerated dose of colchicine (dosage $2 to #3 mg/day), thereby defined as having colchicine-resistant FMF (8) (9) (10) , who were willing and able to comply with the prescribed colchicine treatment, and who agreed to use adequate contraception and to sign an informed consent form. Patients intolerant to the aboveindicated dose levels of colchicine (with intolerance mainly manifested as symptoms of diarrhea or abdominal upset or both) could be included if their dosage was at least 1.5 mg/day. This dose limitation based on colchicine intolerance was applied in order to decrease the dose heterogeneity among participants.
Exclusion criteria. Patients were not eligible for the study if they had any of the following conditions: conditions that allegedly could be worsened by anakinra (active infection, recent [#3 months] live vaccination, pregnancy, and prior or existing malignancy); conditions affecting compliance with the treatment protocol (alcohol or substance abuse, or social and psychological conditions interfering with compliance); conditions that could affect FMF activity (concomitant medication with biologic agents or chemical disease-modifying antirheumatic drugs or systemic steroids, or prior use of IL-1 blockers); conditions that could affect anakinra metabolism (chronic renal failure with a creatinine clearance rate of ,30 ml/minute); and conditions affecting interpretation of FMF activity (a wide range of autoimmune and other autoinflammatory diseases, diabetes mellitus, gastrointestinal diseases such as Crohn's disease, ulcerative colitis, and irritable bowel syndrome, active ischemic cardiovascular disease, congestive heart failure, asthma, chronic obstructive pulmonary disease, and any other condition that, according to the recruiting physician, would fit this latter criterion).
Randomization and blinding. Patients were recruited consecutively (by order of arrival) from our FMF-dedicated clinic, and were randomly assigned, in a blinded manner, to receive treatment with either anakinra or placebo. Assignment to either the anakinra group or the placebo group was based on a predetermined key, unknown to both the investigators and the patients, that was established by an external company (TFS Trial Form Support, Lund, Sweden). The randomization was stratified by sex. During the study, patients continued to receive the treatments they had been taking prior to the study, particularly colchicine. Analgesic drugs used prior to recruitment were allowed as needed, but their use was monitored.
Outcomes. Primary efficacy outcome. The primary efficacy outcome was the difference between the anakinra and placebo groups in the total number of attacks over the study period, adjusted to participation time (number of attacks per patient per month), as well as the difference between the anakinra and placebo groups in the number of patients with a mean of ,1 FMF attack per month.
Secondary efficacy and safety outcomes. The secondary efficacy and safety outcomes included differences between the 2 groups in the number of attacks per FMF site, levels of acutephase reactants, number and severity of adverse events (AEs), quality of life (QoL) as assessed using a 10-cm visual analog scale (VAS), and the use of analgesic agents.
Survival analysis. Survival analysis was performed with an end point of 4 attacks. This 4-attack target was based on the following calculation: the main inclusion criterion (at least 1 attack per month) multiplied by 4 (the study duration).
Modified FMF50 score. Based on the FMF50 score (originally defining response to treatment by at least 50% improvement in 5 of 6 criteria, without worsening in any one criterion), which was first published well after initiation of this study (33) , a modified FMF50 score was constructed, according to which fulfillment of 3 of 4 criteria was considered an improvement. These improvement criteria included the following: $50% decrease in the frequency of all attacks, $50% decrease in the frequency of attacks in the joints, $50% decrease in the levels of either serum amyloid A (SAA) or C-reactive protein (CRP) or normalization of these markers, and $50% increase in QoL values (as a substitute for the patient's global assessment in the original score). Individual comparisons were performed between the baseline and last measurements. The frequency of attacks at baseline was based on each patient's self-report. Any missing data for a paired value (e.g., QoL score at last visit) was considered a failure to achieve improvement in the item determined (e.g., QoL).
Intervention and assessment. Treatment. The study lasted 4 months, during which the patients received daily injections of either anakinra or placebo. Anakinra was self-administered as a subcutaneous injection of 100 mg/day from prefilled syringes, and the placebo treatment (anakinra vehicle) was administered in a similar manner. The distributor of anakinra (Sobi) prepared the study medications. The patients were instructed to record in diaries the injections received, concomitant medications used, FMF attacks experienced, and AEs encountered.
Clinical assessment. Physician examination was performed at the time of randomization, at the termination visit (mandatory), and during other study site visits, if required. Baseline parameters, including the physical examination findings, detailed medical history, mean number of attacks and body sites involved, and QoL evaluation, were obtained by the physician during the initial visit. QoL was also assessed at study termination. The study nurse communicated weekly with the patients by telephone, and patients visited the study site clinic twice (on days 30 and 60) for close monitoring of patient compliance, assistance with the interpretation of symptoms as attacks, and for guidance and care for AEs, including injection site reaction. Patients were encouraged to call the nurse and visit the study site, as necessary. Laboratory tests (blood and urine) and pregnancy tests were performed at each study site visit (on days 0, 30, 60, and 120). Two poststudy telephone calls by the study nurse were scheduled for days 150 and 180, to assess the development of long-term AEs. All study data were recorded in case report forms, including data transferred from patient diaries.
Definition of FMF attacks. Febrile manifestations reported by patients were considered to be attacks only if they met the criteria defining attacks, and were confirmed by one of the study team members (AL). Briefly, the criteria defining an attack included all of the following symptoms: fever of $388C lasting 6 hours to 7 days and accompanied by painful manifestations in either the abdomen (with features consistent with a diagnosis of peritonitis), the chest (with features consistent with a diagnosis of pleuritis), the joints (with features consistent with a diagnosis of lower extremity large joint monoarthritis), or the skin (with features consistent with a diagnosis of erysipeloid rash). A more detailed definition of an FMF attack (2,3,32) is available upon request from the corresponding author.
Evaluation of QoL. Assessment of QoL was performed using a VAS rating, where scores of 0 and 10 indicated the lowest and highest QoL scores, respectively. In their assessment, patients were instructed to consider the overall QoL during the preceding 14 days.
Laboratory tests. Laboratory tests included a complete blood cell count and blood chemistry panel, consisting of liver and renal function tests, electrolytes and urate, CRP levels (normal value #5 mg/liter), SAA levels (normal value #10 mg/liter, at the first and last visit only), and urinalysis (at the first and last visits only).
Safety assessment and recording of AEs. AEs and serious AEs (SAEs) were defined according to the definitions endorsed by the good clinical practice rules for all drug intervention trials, which describe an AE as any untoward medical occurrence in trial patients (regardless of whether it is drug-related), and which describe an SAE as an AE associated with death, a life-threatening condition, hospitalization, persistent or significant disability, congenital anomaly, or medical intervention to prevent any of the above-listed events (more information is available at https://prsinfo.clinicaltrials.gov/results_definitions. html#AdverseEventsDefinition). All AEs were recorded in the study data files, classified as serious or nonserious, and assessed for level of severity (mild, moderate, or severe), expectedness (expected or unexpected), and causality (related or unrelated).
Evaluation and management of injection site reactions are detailed elsewhere (34) (details available upon request from the corresponding author). Of note, since injection site reactions are mostly related to the vehicle of anakinra, it does not unmask blinding.
Data evaluation and statistical analysis. Primary and secondary study outcomes were determined by comparing the mean values between the groups at study termination. Due to the small sample size, statistical analysis was based on the nonparametric Wilcoxon-Mann-Whitney rank sum test and the median test for quantitative parameters. The chi-square test was used for data classified as categorical. A KaplanMeier survival function curve analysis was performed using the log-rank test. Analyses were performed using 2-tailed tests. P values less than or equal to 0.05 were considered statistically significant. Because of dropouts, differences in the total number of attacks, number of attacks per site, number of AEs, and use of analgesics between the anakinra and placebo groups over the study period were adjusted for the actual time of patient participation in the study, and differences in levels of acute-phase reactants and QoL between the groups were based on the last value available.
Originally, based on the assumption of a mean of 2.5 attacks per patient per month at baseline and a rate of 50% improvement with anakinra treatment, a sample size of 20 patients per group was calculated to allow for detection of the differences between the anakinra and placebo groups with a power of 90% (using nQuery Advisor, version 2.1). However, due to slow enrollment and based on actual data, an interim analysis with reevaluation of the sample size was performed. At this point, the evaluation was based on the actual mean of 5 attacks per patient per month at baseline, with a group mean of 1.66 attacks per patient per month in the anakinra group and 3.49 attacks per patient per month in the placebo group, and a common standard deviation of 1.55, which led to a calculated sample size requirement of 12 patients per group, to allow for detection of differences between the anakinra and placebo groups with a power of 80%. Data were obtained, processed, and statistically analyzed at MediStat (a company that specializes in biostatistics, clinical trials, and data management), using SAS software (version 9.3; SAS Institute).
RESULTS
Over a 20-month period (January 2013 through August 2014), 53 patients were assessed for participation in the study; of these, 25 (14 women) were enrolled (12 in the anakinra group and 13 in the placebo group) ( Figure  1 ). All patients signed an informed consent form. Table 1 shows the baseline characteristics of the study population. As shown, the 2 patient groups were comparable with respect to sex, age, mean colchicine dosage, total number of attacks per month, distribution of attack sites, laboratory parameters of inflammation, M694V MEFV mutation carriage, QoL assessment, comorbidities, and the use of concomitant medications (mostly analgesics). Of note, all patients were receiving colchicine at a dosage of $2 mg/ day except for 3 patients (2 in the placebo group and 1 in the anakinra group), who were receiving 1.5 mg/day due to intolerance to higher dosages. The distribution of the specific MEFV genotypes of the studied patients is available upon request from the corresponding author.
Seven patients discontinued the study, all of whom were from the placebo group. The discontinuations were due to what was considered to be treatment failure in 5 patients and due to AEs (1 for pregnancy and 1 for drug allergy) in 2 patients. In the anakinra group, 7 patients had a .90% reduction in their stated attack frequency, while the frequency of attacks improved to a lesser degree in 5 patients. As shown in Table 2 , the primary outcomes were significantly achieved. The mean number of attacks in all sites was lower in the anakinra group than in the placebo group (mean 6 SD 1.7 6 1.7 versus 3.5 6 1.9 attacks per patient per month; P 5 0.037). Moreover, the number of patients with a mean of ,1 attack per month was higher in those receiving anakinra (6 patients versus 0 in the placebo group; P 5 0.005). Table 2 also displays the secondary efficacy outcomes. Statistically significant differences between the groups were observed for some of the secondary efficacy outcomes (number of attacks in the joints and QoL scores), whereas some outcomes failed to show a significant difference (e.g., abdominal and chest attacks). QoL score on 10-cm VAS 4 6 2.3 3.9 6 1.5 Serious comorbidities, no. 4 (n 5 3) † 3 (n 5 2) ‡ Concomitant medications other than colchicine, % of patients 92 92 * For some specific parameters, data shown do not reflect the total number of patients in the treatment group (i.e., 12 in the anakinra group and 13 in the placebo group) because of missing values or because attacks at the specific site did not occur in all patients, or serious comorbidities did not occur in all patients; n values in the data columns show the number of patients for the given parameter. The differences between the anakinra and placebo groups were nonsignificant for all parameters. Except where indicated otherwise, values are the mean 6 SD. ESR 5 erythrocyte sedimentation rate; CRP 5 C-reactive protein; SAA 5 serum amyloid A; QoL 5 quality of life; VAS 5 visual analog scale. † Tachycardia, paroxysmal atrial fibrillation, transient ischemic attack. ‡ Status post bacterial endocarditis and aortic regurgitation, episodic vertigo, panic attacks.
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Two post hoc analyses were performed. To graphically illustrate the efficacy of anakinra over placebo, we performed a survival analysis in which the end point was 4 attacks (Figure 2) . Accordingly, the placebo-treated patients reached the target of 4 attacks significantly faster than the anakinra-treated patients (P 5 0.015 for difference in survival probability between groups).
A second analysis using the modified FMF50 tool (based on the original FMF50 scale) was carried out. The FMF50 was proposed as a measure to evaluate drug efficacy in intervention trials in FMF. Accordingly, 10 of 12 patients in the anakinra group and 4 of 13 patients in the placebo group achieved the modified FMF50 criteria defining improvement (P , 0.008) (Figure 3) . Table 3 presents the secondary outcomes with regard to safety. The safety outcomes were, in general, similar between the 2 patient groups, including the number of AEs, the rate of AEs, associations of AEs with specific organ systems, and associations of AEs with the study drug and severity. No SAEs were recorded, and none of the AEs were graded as severe. Despite use of a lower number of analgesics per patient in the anakinra group compared to the placebo group, the difference did not reach statistical significance.
DISCUSSION
In this study, anakinra, administered subcutaneously at a dosage of 100 mg/day, was superior to placebo in suppressing colchicine-resistant FMF disease activity. Patients with colchicine-resistant FMF treated with anakinra had fewer attacks per patient per month compared to the placebo group, when attacks in all sites were considered (mean 6 SD 1.7 6 1.7 attacks per patient per month versus 3.5 6 1.9 attacks per patient per month; P 5 0.037) and when attacks in each site separately were considered (in the joints, mean 6 SD 0.8 6 1.6 attacks per patient per month More patients treated with anakinra had a mean of ,1 attack per month (6 patients versus none in the placebo group; P 5 0.005). Anakinra-treated patients reached a target of 4 attacks at a much slower rate during the study than did those in the placebo group (mean 6 SD 89.8 6 51.6 days versus 39.6 6 22.2 days; P 5 0.015), and more patients treated with anakinra achieved an improvement response according to the modified FMF50 score (10 of 12 patients versus 4 of 13 placebo-treated patients; P 5 0.008), and according to the QoL score (mean 6 SD VAS score 7.7 6 2.3 versus 4.2 6 2.9; P 5 0.045). This success was not accompanied by a reduction in safety, as AEs in the 2 groups did not differ in the number, rate, severity, or distribution among organ systems. Unfortunately, for unknown reasons, not all patients responded favorably to the same extent. This increased the mean number of attacks in the anakinra group, expanded the standard deviation, and blunted the outcome. It is possible that patients who had not entered remission would have done better had the study been designed to allow for dose escalation in unresponsive patients. This statement is based on prior experience with the use of anakinra in other autoinflammatory diseases (35) , and our experience with other IL-1 blockers in colchicine-resistant FMF, which work at dose levels only above the standard dose in some patients.
Ample reports and observational studies have implied that IL-1 blockers have a role in the prevention of attacks in patients with colchicine-resistant FMF (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) 36) . However, to date, only 1 randomized controlled study of IL-1 blockers, a trial investigating rilonacept, which is a synthetic receptor-like protein that traps the IL-1 cytokine, showed significant reduction in the number of FMF attacks in patients with colchicine-resistant FMF (37) . Thus, our results, analyzed for the first time in a randomized controlled trial, confirm previous observations with regard to the efficacy of anakinra.
The mean number of attacks in each of the FMF sites was lower in the anakinra group than in the placebo group (Table 2) . However, of all sites, the difference between the anakinra and placebo groups reached significance only for attacks in the joints. Indeed, as might be inferred from the findings presented in Table 2 , the difference in mean total number of attacks was mainly driven by the lower number of attacks in the joints. This preferential effect of anakinra on the joints is interesting and particular to the present study. In this respect, anakinra may be complementary to colchicine, a treatment that often fails to prevent attacks in the joints while suppressing activity in other sites. This differential effect of colchicine on attack sites is demonstrated by the baseline parameters in the present study-specifically, by the higher frequency of attacks in the joints compared to attacks in other sites (Table 1) . However, this observation has been reported only scarcely in the literature (12, 38) . Although preliminary, these findings may support a role for dual therapy with colchicine and anakinra in patients with colchicine-resistant FMF.
The main reason, however, to administer colchicine despite achieving control of FMF activity with anakinra is the fear of AA amyloidosis. Zemer et al (39) found that only 4 of 1,000 colchicine-treated patients with FMF developed amyloidosis over a 13-year period, 2 of whom admitted noncompliance. This suggests an extremely low risk of developing amyloidosis in patients receiving colchicine. Compared to historical data from the precolchicine era, the findings in the study by Zemer et al presented a major advance in the prevention of FMF amyloidosis and established the role of colchicine for this condition. Until comparable data are obtained for anakinra, colchicine should remain the mainstay of amyloidosis prevention in colchicine-resistant FMF, and should be administered concomitantly with anakinra. AA amyloidosis of FMF is the most extreme adverse outcome of colchicine-resistant FMF. To date, there is no cure for AA amyloidosis, which, in most cases, progresses to involve all organ systems, other than the central nervous system, and leads to early death (40, 41) . SAA is the serum precursor of amyloid in tissues. A considerable difference in the final mean SAA levels between the anakinra and placebo groups was noted in the current study, although the difference did not reach significance (mean 6 SD 11.1 6 19.1 mg/liter versus 110.3 6 131 mg/ liter; P 5 0.069) ( Table 2 ). Thus, via its reduction in resources for amyloid generation, anakinra appears to be an instrument for halting ongoing amyloid deposition. This role of anakinra was not tested in the present study, but may be inferred from the suppression of SAA and supported by reports of improvement in patients with FMF amyloidosis following anakinra treatment (9, 24, (27) (28) (29) 31, 36) .
FMF attacks in those with colchicine-resistant FMF are only one aspect of the disease burden in FMF. The ill effects of colchicine-resistant FMF on social, familial, financial, educational, cultural, and other aspects of the patient's life may converge and result in lower QoL scores (9, (42) (43) (44) (45) . Indeed, the poor QoL scores declared by the patients at their baseline visit (Table 1 ) reflect the huge impact of colchicineresistant FMF on their daily lives. The significant difference in QoL between the anakinra and placebo groups at the conclusion of this study (P 5 0.045) ( Table 2) is strong evidence for the success of anakinra.
Although it is considered a targeted treatment, anakinra actually addresses the result (high IL-1 levels) and not the cause of colchicine failure; the latter is yet to be determined. We found that colchicine levels in the mononuclear cells of patients with colchicine-resistant FMF were 50% lower than those in the mononuclear cells of colchicine-responsive control patients with FMF. A genetic defect unrelated to MEFV has been proposed to underlie colchicine resistance (9) . Three distinct studies found that a polymorphism in nucleotide 3435 of the MDR1 (multidrug resistant 1) gene, responsible for removal of drugs from cells, is associated with colchicineresistant FMF (46) (47) (48) . However, the statistical significance of this finding was only borderline, and in any case, the expected result is colchicine retention and not elimination. Other mononuclear cell molecules linking colchicine kinetics to inflammation should be investigated to better understand the mechanism of colchicine-resistant FMF.
Unfortunately, the current trial was terminated earlier than had been initially planned. However, the fact that the primary outcome was achieved with a smaller cohort suggests that anakinra is more effective than had been initially thought (i.e., performs better than the 50% improvement that served as the basis for computing the original sample size, as detailed in Patients and Methods). This high competence of anakinra (relative to that predicted) might also be inferred from the results of the modified FMF50 analysis, which showed a .50% improvement in 8 of 12 patients treated with anakinra ( Figure 3 ). In addition, recruitment of patients with an average of 5 attacks per month instead of 2.5 attacks per month (which benefited the interim analysis, as discussed in Patients and Methods) enabled us to display the effectiveness of anakinra even in a population of patients with very severe colchicine-resistant FMF. In this regard, in the only other controlled trial of IL-1 blockers in colchicine-resistant FMF, the patients in whom rilonacept was effective had a less severe disease (a mean attack rate of 3.1 per month) (37) .
With regard to study limitations, the small sample size with large variance between values (e.g., in 1 patient, the initial SAA level was 600 mg/liter and dropped to 20 mg/ liter, whereas for another patient, it dropped from 80 mg/ liter to 30 mg/liter) made the favorable effect of anakinra appear indistinct, to some extent. Nevertheless, the primary and some secondary outcomes were well elucidated.
Due to the short duration of the study, we could not account for long-term safety and efficacy concerns. In other anakinra trials, injection site reactions and infections were reported to be definitely more common in the anakinra group than in the control group. However, in general, the present experience with the use of anakinra in a very wide range of diseases, including RA, adult-onset Still's disease, systemic-onset juvenile idiopathic arthritis, and CAPS, some for a long duration (49, 50) , confirms the safety profile of anakinra. Longer studies on FMF and postmarketing real-life experience are needed to verify the persistence of anakinra efficacy.
The change in group size from 20 patients to 12 or 13 patients reduced the power of the favorable results from 90% to 80%, and this could possibly have been a factor in the lack of fulfillment of some of the secondary outcomes. However, a power of 80% is well-accepted strength in biologic studies, and thus allows for the addition of anakinra to the almost-empty arsenal of treatments for difficult FMF. This minimizes, at least to some extent, this limitation.
Thus, in this small, double-blind, randomized, placebo-controlled trial, anakinra appears to be an effective and safe treatment for colchicine-resistant FMF. It reduces the attack rate, particularly attacks in the joints, and improves QoL. This drug holds hope for thousands of patients who continue to have serious symptoms despite adhering to a colchicine treatment regimen. Future perspectives include determination of the need for concomitant administration of colchicine, understanding of the 860 BEN-ZVI ET AL mechanism of colchicine resistance and targeting it with more specific agents, and elucidation of the role of anakinra in patients with colchicine-resistant FMF, who may also have other inflammatory conditions, as well as evaluation of long-term efficacy and safety concerns.
